Vagus nerve stimulation for patients with tuberous sclerosis complex–related drug‐resistant epilepsy: A prospective cohort study
Epilepsia · 2026
DOI: 10.1002/epi.70350 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Epilepsia, 2026. Verfasst von Tinghong Liu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Functional Neurosurgery Department, National Center for Children's Health, Beijing Children's Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Vagus Nerve Stimulation, Tuberous Sclerosis, Drug Resistant Epilepsy. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Beijing Municipal Science & Technology Commission, Administrative Commission of Zhongguancun Science Park, Beijing Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
Tuberous sclerosis complex (TSC) is a genetic multisystem disorder with a high prevalence of drug‐resistant epilepsy (DRE), significantly affecting patients' quality of life. For patients with TSC lacking localizing epileptogenic tuber, resective surgery is often not feasible. Vagus nerve stimulation (VNS) has been proposed as an alternative surgical therapy, although robust evidence in TSC‐related DRE remains limited.
Methods
A prospective cohort study was conducted between December 2019 and July 2024 across multiple epilepsy centers in China. Seventy patients with TSC‐related DRE were enrolled, all lacking resectable epileptogenic tubers on multidisciplinary evaluation and ineligible for resective surgery. Participants were divided into VNS ( n = 20) and medication‐only ( n = 50) groups based on actual treatment, and followed for up to 3 years. Seizure outcomes, anti‐seizure medication use, IQ, and quality of life were evaluated longitudinally.
Results
The VNS group demonstrated significantly higher response rates at 1‐, 2‐, and 3‐year follow‐ups (65%–75%) compared to the medical treatment group (31%–36%). Median and average seizure frequency reductions were also greater in the VNS group. VNS was associated with significantly higher treatment response than medication, with the relative risk (RR) of response being 1.81 (95% confidence interval [CI]: 1.22–2.67), 2.21 (95% CI: 1.42–3.44), and 2.42 (95% CI: 1.49–3.93) at 1‐, 2‐, and 3‐year follow‐ups ( p < 0.01). Seizure recurrence was significantly lower in the VNS group ( p < 0.01). Moreover, VNS treatment led to significant reductions in anti‐seizure medication (ASM) use and improvement in intelligence quotient and quality of life at the 2‐year follow‐up. Treatment modality was the only independent predictor of clinical response. VNS was well tolerated, with only mild surgical complications and no permanent adverse events reported. Significance VNS significantly improves seizure control, cognitive outcomes, and quality of life, with a favorable safety profile. These findings support VNS as an effective and safe alternative for this specific TSC population. Future randomized controlled trials are warranted to further validate these results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Functional Neurosurgery Department, National Center for Children's Health, Beijing Children's Hospital, Capital Medical University, Beijing, China.
- Department of Functional Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, China.
- Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Department of Neurosurgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
- Neurology Departmemt, Epilepsy Center, Shenzhen Children's Hospital, Guangdong, China.
- Department of Pediatrics, Xiangya Hospital, Central South University, Changsha, China.
ORCID-Profile: Tinghong Liu, Zhirong Wei, Jian Zhou, Rui Zhao, Jinshan Xu, Zhiqiang Yan, Dezhi Cao, Beibei Chen, Jing Peng, Jiuluan Lin, Yao Meng, Yaguang Peng, Li Wang, Xuejing Wang, Feng Zhai, Shuli Liang
Förderung
- Beijing Municipal Science & Technology Commission, Administrative Commission of Zhongguancun Science Park
- Beijing Natural Science Foundation
- National Natural Science Foundation of China
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Liu, T., Wei, Z., Zhou, J., Zhao, R., Kuang, S., Xu, J., Yan, Z., Cao, D., Chen, B., Peng, J., Lin, J., Meng, Y., Peng, Y., Wang, L., Wang, X., Zhai, F., & Liang, S. (2026). Vagus nerve stimulation for patients with tuberous sclerosis complex–related drug‐resistant epilepsy: A prospective cohort study. Epilepsia. https://doi.org/10.1002/epi.70350
Vancouver
Liu T, Wei Z, Zhou J, Zhao R, Kuang S, Xu J, et al. Vagus nerve stimulation for patients with tuberous sclerosis complex–related drug‐resistant epilepsy: A prospective cohort study. Epilepsia. 2026. doi:10.1002/epi.70350
BibTeX
@article{Liu2026,
author = {Liu, Tinghong and Wei, Zhirong and Zhou, Jian and Zhao, Rui and Kuang, Suhui and Xu, Jinshan and Yan, Zhiqiang and Cao, Dezhi and Chen, Beibei and Peng, Jing and Lin, Jiuluan and Meng, Yao and Peng, Yaguang and Wang, Li and Wang, Xuejing and Zhai, Feng and Liang, Shuli},
title = {Vagus nerve stimulation for patients with tuberous sclerosis complex–related drug‐resistant epilepsy: A prospective cohort study},
journal = {Epilepsia},
year = {2026},
doi = {10.1002/epi.70350}
}
EUVIMED